This brochure provides a detailed overview of Ace Therapeutics' capabilities in developing autism models, covering a range of modeling strategies. We present representative case data generated from our technology platform to demonstrate model validity and therapeutic response.

Key highlights covered in this brochure include:

Gene-Modified Autism Models

We utilize gene-edited autism models to provide pharmacodynamic evaluation services for candidate drugs.

• SHANK3B Models: Recapitulate core ASD phenotypes including social deficits and repetitive behaviors.
• CNTNAP2 Models: Reflect synaptic dysfunction and neuronal connectivity alterations relevant to ASD pathology.
• TBX1 Models: Exhibit social deficits, repetitive behaviors, and cognitive inflexibility—validated through comprehensive behavioral testing.

VPA-Induced Autism Model

The valproic acid (VPA)‑induced model is one of the most widely used environmental models for ASD, based on prenatal exposure to VPA. This brochure presents detailed case data from our VPA model.

• Study Design: Pregnant rats received VPA treatment on embryonic day 12.5 (E12.5), and the offspring underwent behavioral assessments at multiple postnatal time points.
• Key Behavioral Endpoints: Open field test (assessing anxiety and stereotyped behaviors) and three‑chamber social test (measuring social interaction deficits).
• Pharmacological Intervention: Data demonstrate the effects of the test compound, showing trends toward amelioration of repetitive behaviors and social deficits. These results validate the model's responsiveness to potential therapeutics.

Comprehensive Behavioral Testing Platform

Our autism model validation relies on a robust suite of behavioral assays, including:

• Three-Chamber Social Interaction Test: Quantifies social approach and preference.
• Open Field Test: Assesses locomotor activity, anxiety-like behavior, and repetitive self-grooming.
• Additional assays available for cognitive flexibility and sensory processing.

Histological & Imaging Support

Beyond behavioral phenotyping, our platform integrates slide preparation, histological staining, and advanced imaging to evaluate neuropathological correlates, enabling deeper mechanistic insights.

This brochure serves as a practical guide to our autism modeling and preclinical efficacy evaluation capabilities. It demonstrates how Ace Therapeutics supports your ASD research across the entire spectrum, from target validation to preclinical efficacy assessment.

Download the brochure to explore our full autism modeling capabilities and discover how our integrated platform can accelerate your ASD drug development programs.

You might be interested in...